| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | blebbistatin | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.0024 | 1 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.0018 | 1 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.0028 | 1 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | -0.0033 | 1 |